BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20260101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270224
DTSTAMP:20261106T112904Z
CREATED:20261106T112904Z
LAST-MODIFIED:20261106T112904Z
UID:44719-1803254400-1803427199@www.pharmajournalist.com
SUMMARY:SmartLab Exchange Europe 2027
DESCRIPTION:SmartLab Exchange Europe 2027 is the invitation-only forum for senior laboratory\, digital transformation\, data and R&D leaders responsible for accelerating innovation and driving digital transformation across the life sciences and process industries. Bringing together decision-makers from pharmaceutical\, biotech\, FMCG\, food & beverage and chemicals organisations\, the event provides a unique platform to explore the technologies\, strategies and operating models shaping the future of scientific research and development. \nAs organisations seek to operationalise artificial intelligence and advanced digital technologies\, many continue to face challenges including fragmented data environments\, disconnected laboratory systems\, workforce adoption barriers and difficulties scaling AI beyond proof-of-concept projects. SmartLab Exchange Europe 2027 addresses these challenges by focusing on practical\, real-world approaches to achieving successful R&D transformation and delivering measurable business value from digital initiatives. \nThe 2027 programme explores key industry priorities including AI-ready data foundations\, trusted AI governance\, laboratory orchestration\, connected scientific ecosystems\, workforce transformation and the emergence of self-driving laboratories. Through a combination of peer-led case studies\, panel discussions\, think tanks\, interactive roundtables and one-to-one meetings\, attendees will gain actionable insights from organisations successfully implementing AI\, automation and digital innovation across laboratory and R&D environments. \nAttendees will have the opportunity to benchmark their strategies against industry peers\, discover how leading organisations are building scalable AI capabilities\, and explore approaches to improving data quality\, interoperability and digital adoption across the laboratory landscape. The event also examines how organisations can create trusted foundations for AI\, connect previously siloed systems and transform laboratory operations to support faster\, more informed scientific decision-making. \nThe event features senior leaders from organisations including AstraZeneca\, Novartis\, Johnson & Johnson\, Kenvue and Henkel\, alongside an extensive faculty of laboratory\, digital and R&D transformation experts. Designed for leaders shaping the future of laboratory operations and scientific innovation\, SmartLab Exchange Europe 2027 offers a valuable opportunity to exchange best practices\, explore emerging technologies and build the partnerships needed to accelerate product development and unlock the full potential of AI-powered R&D. \nTo know more visit: https://bit.ly/4BHlPdJ
URL:https://www.pharmajournalist.com/event/smartlab-exchange-europe-2027/
LOCATION:Leonardo Royal Hotel Amsterdam\, Paul van Vlissingenstraat 24\, Amsterdam\, 1096 BK\, Netherlands
ORGANIZER;CN="IQPC Exchange":MAILTO:enquire@iqpcexchange.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270226
DTSTAMP:20261028T115729Z
CREATED:20261028T115729Z
LAST-MODIFIED:20261028T115729Z
UID:44627-1803340800-1803599999@www.pharmajournalist.com
SUMMARY:3rd Annual TRP Target Selection & Drug Design Summit
DESCRIPTION:The 3rd Annual TRP Target Selection & Drug Design Summit is the industry-dedicated discovery and preclinical forum for advancing the next generation of targeted radiopharmaceutical therapies. Taking place in Boston from February 23-25\, 2027\, the summit will unite more than 100 experts from across discovery\, biology\, medicinal chemistry\, radiochemistry\, ADME/DMPK\, toxicology\, radiobiology\, dosimetry\, preclinical development\, translational science\, and business development. \nAs established targets such as PSMA become increasingly crowded\, the meeting will help radiopharmaceutical developers identify novel targets\, explore new disease settings\, and create differentiated candidates with stronger clinical potential. Attendees will examine how clinically validated targets from ADCs\, RDCs\, immuno-oncology\, and other targeted modalities can be assessed and translated into radioligand therapy programs. \nThe agenda will explore emerging targets across CAIX\, MSLN\, the brain\, extracellular matrix\, and leukocytes\, alongside the biological factors that determine suitability for radiopharmaceutical development. Discussions will also cover targeting moieties\, linkers\, chelators\, radionuclide selection\, biodistribution\, kinetic imaging\, total-body PET\, digital SPECT\, computational biology\, dosimetry\, organ-specific toxicity\, and preclinical safety strategy. \nTwo interactive pre-conference workshops will provide focused learning on using advanced imaging and computational biology to identify high-potential targets\, as well as mining clinical validation from other therapeutic modalities to accelerate target selection. Across the main conference\, presentations\, roundtables\, case studies\, and networking sessions will help attendees benchmark candidate design and determine the evidence required to advance programs confidently toward the clinic. \nWith contributions from experts representing Bayer\, AstraZeneca\, Molecular Partners\, Mariana Oncology\, Harvard Medical School\, United Theranostics\, Ratio Therapeutics\, Affibody\, and other leading organizations\, the summit offers a focused opportunity to improve target selection\, strengthen drug design\, and build safer\, more differentiated radiopharmaceutical pipelines. \nTo know more visit: https://ter.li/ugtcnsbo
URL:https://www.pharmajournalist.com/event/3rd-annual-trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR